Health and Fitness Health and Fitness
Thu, November 15, 2012
Wed, November 14, 2012
Tue, November 13, 2012
Mon, November 12, 2012
Sun, November 11, 2012
Sat, November 10, 2012
Fri, November 9, 2012
Thu, November 8, 2012
Wed, November 7, 2012
Tue, November 6, 2012
Mon, November 5, 2012
Sat, November 3, 2012
Fri, November 2, 2012
Thu, November 1, 2012
Wed, October 31, 2012

OncoGenex Pharmaceuticals to Present at Upcoming Investor Conference


//health-fitness.news-articles.net/content/2012/ .. -to-present-at-upcoming-investor-conference.html
Published in Health and Fitness on Friday, November 9th 2012 at 4:00 GMT by Market Wire   Print publication without navigation


OncoGenex Pharmaceuticals to Present at Upcoming Investor Conference

BOTHELL, WA and VANCOUVER, BC, Nov. 9, 2012 /PRNewswire/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: [ OGXI ]) announced today that Scott Cormack, President and Chief Executive Officer, will provide a corporate presentation at the Lazard Capital Markets Healthcare Conference on Wednesday, November 14, 2012 at 10:00 a.m. ET at the Pierre Hotel in New York City.

Live audio webcasts can be accessed through the Investor Relations page of the OncoGenex website at [ www.oncogenex.com ]. Webcast replays will be archived for 60 days.

About OncoGenex
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer. OGX-427 is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development. More information is available at [ www.OncoGenex.com ]

SOURCE OncoGenex Pharmaceuticals, Inc.




Publication Contributing Sources